Abstract library

1334 results for "pancreatic metastasis".
#2689 Correlation between Immunohistochemical Markers Expression and Lymph Node Metastasis in Gastroenteropancreatic Neuroendocrine Neoplasms: A Nation-Wide 10-Year Retrospective Clinical Epidemiological Study in China
Introduction: Previous research on the correlation between different pathological features and the development of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is rare in China.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Huan Yang
Authors: Yang H, Shi S, Zhang S, Ji Y, ...
#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours
Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Anguraj Sadanandam
#2937 Brain Metastasis in Patients with Neuroendocrine Neoplasia of Gastroenteropancreatic Origin: A Single Centre Experience
Introduction: Brain metastasis (BrMet) in patients (pts) with neuroendocrine neoplasia (NEN) of gastroenteropancreatic (GEP) origin is extremely rare. Data on management and outcome are limited.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Javad Saghebi
Authors: Saghebi J, Hicks R, Michael M, Kong G, ...
#2843 Metastatic Risk in Pancreatic Neuroendocrine Tumors: A 16-Year Experience from Bogotá, Colombia. A Series Cases
Introduction: Pancreatic neuroendocrine tumors (pNET) are rare, have a wide range of phenotypes, increase incidence in recent years; which represents a challenge in diagnosis, treatment, and follow-up
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Deyanira González Devia
#2685 Apatinib Inhibits Tumor Growth and Angiogenesis in PNET Models
Introduction: Angiogenesis has a pivotal role in the growth and metastasis of pancreatic neuroendocrine tumors (PNETs). Apatinib inhibits angiogenesis as a highly selective KDR inhibitor and has been used to treat advanced gastric cancer and malignancies in clinical settings. However, the efficacy of apatinib in PNETs remains unclear.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Shan Wu
Authors: Wu S, Zhou J, Guo J, Hua Z, ...
#2733 Pancreatic Metastases Originating from Intestinal Neuroendocrine Tumours
Introduction: Pancreatic metastases are rare, accounting for 1 to 2% of pancreatic tumours. Data on pancreatic metastases of intestinal NETs are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Anja Rinke
#2848 Correlation between Clinicopathological Features and Distant Metastases in Pancreatic Neuroendocrine Neoplasm: A National Multicenter 10-Year Retrospective Study
Introduction: The incidence of pancreatic neuroendocrine neoplasm (PNEN) is increasing, and the prognosis of patients with PNEN is quite different.So, it is of great significance to study the effect of different pathological features on the prognosis of patients with PNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Xinyi Zhu
Authors: Zhu X, Yang H, Lu H, Shi S, ...
#2841 Novelties in Primary and Metastatic GEP-NENs Clinical Outcome Investigation
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) WHO classification, using strict cut-offs, should reflect their biological features. In real world, strict cut-offs not adequately segregate prognostic groups, in particular on metastasis (M).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Massimo Milione
#2763 Incidence and Outcome of Brain Metastasis in Patients Diagnosed with Neuroendocrine Neoplasm
Introduction: Brain metastases are rarely reported in patients with neuroendocrine carcinoma of non-lung origin and neuroendocrine tumors (NETs) of the gastroenteropancreatic or bronchopulmonary system.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#2899 Using Long-Acting Somatostatin Analogue as Adjuvant Therapy for Post Resection Grade 2 Pancreatic Neuroendocrine Tumor: Interim Results from an Ongoing Multicenter Real-World Study in China
Introduction: Surgery was the preferred treatment in patients with resectable pancreatic neuroendocrine tumor (pNET), but recurrent lesion relapsed frequently within a short time. It was controversial whether patients with pNET need adjuvant therapy after surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Xiaohan Shi
Authors: Shi X, Xu X, Zhang Y, Gao S, ...